Compare Illumina, Inc. (ILMN) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Illumina, Inc. trades at $191.04 (market cap $27.94B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.84 (market cap $77.37B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.8× Illumina, Inc.'s market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MDLZ | |
|---|---|---|
Market Cap | $27.94B | $77.37B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $70.75 |
52-Week Low | $91.00 | $51.51 |
Enterprise Value | $29.33B | $97.46B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Mondelez International (MDLZ) trades at $60.15, down 1.39% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 28.77% gross margins and has beaten earnings estimates for three consecutive quarters. Recent corporate developments include a new CFO appointment and continued dividend payments, while analyst consensus remains strongly positive with a $68 price target representing 13% upside potential.
The outlook for MDLZ appears favorable with consistent earnings beats and solid dividend yield, though investors face risks from margin compression and commodity price volatility. Wall Street's bullish stance is supported by the company's market leadership in snacks and innovation pipeline, but execution on volume growth remains critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
